Table 3.

Central retinal vein, central retinal artery occlusion, and amaurosis fugax after the use of exogenous estrogens or estrogen agonists in six women subsequently shown to have inherited or acquired thrombophilia

Case #	Age	Coagulation disorders	Exogenous estrogen or estrogen agonist	Duration of estrogen or estrogen agonist use prior to ocular thrombotic event
Of 77 women with central retinal vein occlusion
1	51	High factor XI	Nolvadex	5 years
2	53	High serum homocysteine	Estrogen–testosterone	11 months
3	42	High serum homocysteine	Estrogen–progestin oral contraceptive	2 years
4	37	Lupus anticoagulant, high factor XI	Estrogen–progestin oral contraceptive	11 months
Of eight women with central retinal artery occlusion
5	55	High anticardiolipin antibody IgG	Conjugated estrogen tablets	8 years
Of eleven women with amaurosis fugax
6	79	Protein S deficiency	Conjugated estrogen tablets	2 years

Abbreviation: Ig, immunoglobulin.